Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Markus Essler
Immunogenic cell death as a mechanism of synergy between sunitinib and 177 Lu-DOTATATE peptide receptor radionuclide therapy in pancreatic neuroendocrine tumors
Abstract Peptide receptor radionuclide therapy (PRRT) with ¹⁷⁷Lu-DOTATATE improves outcomes in neuroendocrine tumors (NETs), yet durable disease control remains limited in progressive pancreatic NET (pNET) and higher-grade disease. Combinations that enhance PRRT efficacy may be advantageous. As sunitinib has radiosensitizing and immunomodulatory effects, we explored the clinical activity and mechanistic basis of combining sunitinib with PRRT.
Habenula volume alterations in adults born very preterm
Abstract Preterm birth is a major risk factor for childhood psychopathology, including higher rates of anxiety and avoidant personality traits persisting into adulthood. While extensive research has documented volumetric reductions in various brain structures associated with emotional processing in preterm individuals, the habenula, a key component in affective and reward processing, has not yet been studied in this context.
Quantifying the Renal Impact of [177Lu]Lu-PSMA-617: A Longitudinal Analysis of Real-World Data from the LUMEN Registry - Beyond the Abstract
The success story of [177Lu]Lu-PSMA-617 is one of the most exciting developments in modern GU oncology. For patients with pre-treated metastatic castration-resistant prostate cancer (mCRPC), this targeted radioligand therapy has provided a crucial last-line option. However, debate has emerged regarding its collateral adverse events—specifically, to the kidneys.
Quantifying the Renal Impact of [ 177 Lu]Lu-PSMA-617: A Longitudinal Analysis of Real-World Data from the LUMEN Registry
mCRPC 177Lu PSMA kidney eGFR With the expanding clinical application of [177Lu]Lu-PSMA-617 for patients with metastatic castration-resistant prostate cancer (mCRPC), a comprehensive understanding of its long-term safety profile is essential.
Impact of Initial Prostate-Specific Membrane Antigen PET/CT Staging and Prostate-Specific Membrane Antigen-Targeted Biopsy on Treatment Decisions in Prostate Cancer: Results from the Phase 2 DEPROMP Trial | Journal of Nuclear Medicine
Thank you for your interest in spreading the word on Journal of Nuclear Medicine. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.
Key learnings from concordant systematic biopsies in prostate‐specific membrane antigen positron emission tomography/computed tomography‐guided prostate biopsies: Enhancing targeting accuracy
1 INTRODUCTION Given the emerging role of 68Ga-Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA-PET/CT) in prostate cancer (PCa), strategies for its use in primary diagnosis are currently under investigation.1-3 An advantage of PSMA-PET/CT is its ability to provide complete disease staging as well as an assessment of the local tumor extent in the prostate.4 In Addition, PSMA-PET/CT is equivalent to magnetic resonance imaging (MRI) in reliably...
177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer and Prior 223Ra (RALU Study)
RESULTS In total, 133 patients with mCRPC were treated with 223Ra and subsequent 177Lu-PSMA. The patient disposition is shown in Supplemental Table 1 (supplemental materials are available at http://jnm.snmjournals.org). Baseline demographics and clinical characteristics at the start of 177Lu-PSMA therapy are provided in Table 1. Patients had an Eastern Cooperative Oncology Group performance status of either 1 (82/133, 62%) or 2 (51/133, 38%).
Safety and Survival Outcomes of 177Lu-Prostate-Specific Membrane Antigen Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer with Prior 223Ra treatment: The RALU Study
Abstract The radium lutetium (RALU) study evaluated the feasibility of sequential α- and β-emitter use in patients with bone-predominant metastatic castration-resistant prostate cancer. Methods: This preplanned interim retrospective analysis investigated safety and survival outcomes with 177Lu-PSMA in patients treated with prior 223Ra. Results: Forty-nine patients were evaluated. Patients received a median of 6 223Ra injections; 59% of patients received at least 4 177Lu-PSMA cycles.
Reply to Bingzhi Wang, Huan Deng, and Lan Cao's Letter to the Editor re: Hojjat Ahmadzadehfar, Markus Essler. Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning. Eur Urol. In press. https://doi.org
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. We read with great interest the comments of Wang et al in response to our letter [1] regarding the paper by Perera et al. [2]. Wang et al.
Prostate-specific Membrane Antigen Imaging: A Game Changer in Prostate Cancer Diagnosis and Therapy Planning
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Prostate-specific membrane antigen (PSMA) is an enzyme that is significantly overexpressed in prostate cancer cells and can be used as a target for diagnosis and therapy.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Markus
Contact Markus, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack